Literature DB >> 28461066

Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008-2011.

Nicolas L Gilbert1, Jenny Rotondo2, Janna Shapiro3, Lindsey Sherrard2, William D Fraser4, Brian J Ward3.   

Abstract

Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n=1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5IU/mL, 5-10IU/mL, and ≥10IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08-16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45-10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07-6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Canada; Immunoglobulin G; Postpartum vaccination; Pregnancy; Rubella

Mesh:

Substances:

Year:  2017        PMID: 28461066     DOI: 10.1016/j.vaccine.2017.04.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

2.  Sero-prevalence of rubella among pregnant women in Sub-Saharan Africa: a meta-analysis.

Authors:  Zemenu Yohannes Kassa; Siraj Hussen; Solomon Asnake
Journal:  Hum Vaccin Immunother       Date:  2020-03-20       Impact factor: 3.452

3.  Seroprevalence of Rubella Virus-specific Antibodies in Women and the Diagnostic Efficacy of Enzyme-linked Immunoassay and Rapid Immunochromatographic Tests.

Authors:  Praveen R Shahapur; Venkataramana Kandi
Journal:  Cureus       Date:  2020-03-12

4.  Epidemiological changes in rubella IgG antibody levels detected in antenatal women from a retrospective rubella seroprevalence study.

Authors:  Ciara O'Connor; David Le Blanc; Richard J Drew
Journal:  Ir J Med Sci       Date:  2017-12-05       Impact factor: 2.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.